The information on this site is intended for healthcare professionals in the United States and is not intended for the general public.

i am a healthcare professional i am not a healthcare professional
JANUVIA® (sitagliptin)

Savings Offer

Learn more about a savings offer for your eligible patients. Restrictions apply. Please See Terms and Conditions.

Free 30-Day Supply Voucher

Give vouchers to your patients who qualify for a free 30-day supply.

Merck Patient Assistance Program

This program provides Merck medicines for free to eligible uninsured patients who, without our assistance, could not afford these medicines. Prescriptions, including refills, can be shipped directly to a patient’s home.

Patient Education Handouts

Print or e-mail these informative,
easy-to-understand handouts. You can even personalize the handouts with your practice’s information.

Mobile App for Patients With Diabetes

With the Mobile Application for Diabetes from VreeTM, your patients can instantly access diabetes info—plus track their blood glucose, medications, diet, and exercise between visits.

Selected Important Risk Information About JANUMET

There have been postmarketing reports of serious hypersensitivity reactions in patients treated with sitagliptin, one of the components of JANUMET, such as anaphylaxis, angioedema, and exfoliative skin conditions including Stevens-Johnson syndrome. Because these reactions are reported voluntarily from a population of uncertain size, it is generally not possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Onset of these reactions occurred within the first 3 months after initiation of treatment with sitagliptin, with some reports occurring after the first dose. If a hypersensitivity reaction is suspected, discontinue JANUMET, assess for other potential causes for the event, and institute alternative treatment for diabetes.

Please read the Boxed Warning for JANUMET about lactic acidosis.

Selected Important Risk Information About JANUVIA

In clinical studies, the adverse reactions reported, regardless of investigator assessment of causality, in >5% of patients treated with JANUVIA as monotherapy and in combination therapy and more commonly than in patients treated with placebo, were upper respiratory tract infection, nasopharyngitis, and headache.